Literature DB >> 27579692

Cannabis and Pediatric Inflammatory Bowel Disease: Change Blossoms a Mile High.

Edward J Hoffenberg1, Heike Newman, Colm Collins, Sally Tarbell, Kristina Leinwand.   

Abstract

The trend toward decriminalization of cannabis (marijuana) continues sweeping across the United States. Colorado has been a leader of legalization of medical and recreational cannabis use. The growing public interest in the medicinal properties of cannabis and its use by patients with a variety of illnesses including inflammatory bowel disease (IBD) makes it important for pediatric gastroenterologists to understand this movement and its potential effect on patients. This article describes the path to legalization and "medicalization" of cannabis in Colorado and the public perception of safety despite the known adverse health effects of use. We delineate the mammalian endocannabinoid system and our experience of caring for children and adolescents with IBD in an environment of increasing awareness and acceptance of its use. We then summarize the rationale for considering that cannabis may have beneficial and harmful effects for patients with IBD. Finally, we highlight the challenges federal laws impose on conducting research on cannabis in IBD. The intent of this article is to inform health care providers about the issues around cannabis use and research in adolescents and young adults with IBD.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27579692      PMCID: PMC5250561          DOI: 10.1097/MPG.0000000000001393

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  25 in total

1.  Modulation of the immune system in cannabis users.

Authors:  Roberta Pacifici; Piergiorgio Zuccaro; Simona Pichini; Pere N Roset; Sandra Poudevida; Magi Farré; Jordi Segura; Rafael De la Torre
Journal:  JAMA       Date:  2003-04-16       Impact factor: 56.272

Review 2.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

Review 3.  The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract.

Authors:  Federico Massa; Martin Storr; Beat Lutz
Journal:  J Mol Med (Berl)       Date:  2005-08-26       Impact factor: 4.599

4.  The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors.

Authors:  Jennifer L Shoemaker; Biny K Joseph; Michael B Ruckle; Philip R Mayeux; Paul L Prather
Journal:  J Pharmacol Exp Ther       Date:  2005-05-18       Impact factor: 4.030

5.  Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation.

Authors:  Giuseppe D'Argenio; Marta Valenti; Giuseppe Scaglione; Vittorio Cosenza; Italo Sorrentini; Vincenzo Di Marzo
Journal:  FASEB J       Date:  2006-01-10       Impact factor: 5.191

6.  Use of Dronabinol Improves Appetite and Reverses Weight Loss in HIV/AIDS-Infected Patients.

Authors:  Edwin DeJesus; Barry M Rodwick; Daniel Bowers; Calvin J Cohen; Daniel Pearce
Journal:  J Int Assoc Physicians AIDS Care (Chic)       Date:  2007-06

Review 7.  Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects.

Authors:  A A Izzo; M Camilleri
Journal:  Gut       Date:  2008-04-08       Impact factor: 23.059

Review 8.  Cannabinoids, endocannabinoids, and related analogs in inflammation.

Authors:  Sumner H Burstein; Robert B Zurier
Journal:  AAPS J       Date:  2009-02-06       Impact factor: 4.009

9.  Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue.

Authors:  Lucia Marquéz; Juan Suárez; Mar Iglesias; Francisco Javier Bermudez-Silva; Fernando Rodríguez de Fonseca; Montserrat Andreu
Journal:  PLoS One       Date:  2009-09-04       Impact factor: 3.240

10.  Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors.

Authors:  Maria Teresa Cencioni; Valerio Chiurchiù; Giuseppina Catanzaro; Giovanna Borsellino; Giorgio Bernardi; Luca Battistini; Mauro Maccarrone
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

View more
  3 in total

1.  Is Cannabis of Potential Value as a Therapeutic for Inflammatory Bowel Disease?

Authors:  Timna Naftali
Journal:  Dig Dis Sci       Date:  2019-10       Impact factor: 3.199

Review 2.  The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information.

Authors:  Arun Swaminath; Eric P Berlin; Adam Cheifetz; Ed Hoffenberg; Jami Kinnucan; Laura Wingate; Sarah Buchanan; Nada Zmeter; David T Rubin
Journal:  Inflamm Bowel Dis       Date:  2019-02-21       Impact factor: 5.325

3.  Cannabinoid Receptor-2 Ameliorates Inflammation in Murine Model of Crohn's Disease.

Authors:  Kristina L Leinwand; Ashleigh A Jones; Rick H Huang; Paul Jedlicka; Daniel J Kao; Edwin F de Zoeten; Soumita Ghosh; Ruin Moaddel; Jan Wehkamp; Maureen J Ostaff; Jutta Bader; Carol M Aherne; Colm B Collins
Journal:  J Crohns Colitis       Date:  2017-10-27       Impact factor: 9.071

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.